Table 4. . Summary of key systemic therapy studies.
| Study | No. of patients | Treatment | Intracranial response (%) | Median progression-free survival (months) | Median overall survival (months) | Ref. |
|---|---|---|---|---|---|---|
| Agarwala et al. | 151 | Temozolomide | Chemo-naive: 7 Prior chemo: 1 |
1.2 1.0 |
3.5 2.2 |
[58] |
| Jacquillat et al. | 39 | Fotemustine | 28.2 | NR | 26 weeks | [61] |
| Avril et al. | 229 (43 with BMs) | Fotemustine Dacarbazine |
5.9 0 |
NR | NR | [64]† |
| Margolin et al. | 72 | Ipilimumab | No steroid: 16‡ With steroid: 5 |
1.5 1.2 |
7 3.7 |
[65] |
| Queirolo et al. | 146 | Ipilimumab | NR | 2.8 | 4.3 | [66]§ |
| Dummer et al. | 24 | Vemurafenib | 16 | 3.9 | 5.3 | [67] |
| Kefford et al. | 146 | Vemurafenib | No prior local therapy: 21 Prior local therapy: NR |
3.74 3.94 |
7.06 9.53 |
[68] |
| Long et al. | 172 | Dabrafenib | No prior local therapy: 39.2¶ Prior local therapy: 30.8¶ |
16.1 weeks¶ 16.6 weeks¶ |
33.1 weeks¶ 31.4 weeks¶ |
[69] |
†Randomized.
‡At 12 weeks.
§Retrospective.
¶V600E-positive.
BM: Brain metastases; NR: Not reported.